Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gamunex-C for Autoimmune POTS (iSTAND)
NCT03919773Phase 2Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- Oct 2018
- Primary completion
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of intravenous immunoglobulin G in postural orthostatic tachycardia syndrome (POTS), sponsored by UT Southwestern Medical Center. Primary endpoint: Composite Autonomic Symptom Score 31 at 13 weeks. Started Oct 2018; status: completed.
02
Drugs
intravenous immunoglobulin G
03
Conditions
postural orthostatic tachycardia syndrome (POTS)
Beyond the preview
Go deeper on NCT03919773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03919773.